BillionToOne Secures Additional $48.5M; Up To $35M Term Loan Facility 

BillionToOne laboratory

BillionToOne, Inc., a Menlo Park, CA-based molecular diagnostics company, secured an additional $48.5m of funding, as well as upsized its term loan facility with access to up to $35m.

The $48.5m funding consisted of additional investments from Series C investors including Libertus Capital, Hummingbird Ventures, Baillie Gifford, Adams Street Partners, Neotribe Ventures, Fifty Years VC, Norwest Venture Partners, and Time BioVentures. The upsized term loan facility was provided by existing lender Bridge Bank.

The company intends to use the funds to continue to scale its UNITY Screen and support its plan to commercialize its liquid biopsy product line, Northstar Select and Northstar Response, in early 2023.

Led by CEO Oguzhan Atay, BillionToOne is a molecular diagnostics company with a mission to make molecular diagnostics more accurate, efficient, and accessible for all, via its Quantitative Counting Templates, and QCTs. The UNITY Screen™ is a non-invasive prenatal test (NIPT) that assesses fetal risk for recessive conditions and red blood cell antigen incompatibility, in addition to aneuploidies.